|
Name: MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine))
Type: Opioid
AKA: MT-45
|
|
II. Natural Derivative
Synthetic substance, no natural derivative
 |
|
III. Chemical Profile (IUPAC name)
|
|
IV. History
1956:
The discovery of the first piperazine derivatives, 4-methylpiperazine (4-MP) and 4-phenylpiperazine (4-PP), was made by Dr. Robert W. Leflar (1915-1994). Leflar and his colleagues were studying a family of substances called phenothiazines, which had previously been synthesized by chemists. 4-MP is an important central nervous system (CNS) drug, while 4-PP is used as a general anesthetic.
1957:
The first clinical use of 4-MP in humans was by Dr. Robert Leflar and Dr. Robert M. Brown, who were studying 4-MP’s properties as a tranquilizer and an anesthetic. Dr. Brown began using 4-MP as a tranquilizer in 1957, and Dr. Leflar began using 4-MP as an anesthetic in 1958.
|
|
V. Legal Information
MT-45, a synthetic opioid, is classified as a Schedule I controlled substance in the US, making it illegal. Many countries have similarly banned it due to its high potential for abuse and health risks. The UNODC monitors synthetic opioids, emphasizing the need for international regulation. Trends show increasing global control measures to address the opioid crisis.
US Federal Schedule - I
Schedule I drugs, substances, or chemicals are defined as drugs with no currently accepted medical use and a high potential for abuse. Some examples of Schedule I drugs are: heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), 3,4-methylenedioxymethamphetamine (ecstasy), methaqualone, and peyote.
Key US Federal Policies:
Controlled Substances Act. Public Law: Public Law 91-513 (text can be found on GovInfo) (https://www.dea.gov/drug-information/csa). Date enacted: October 27, 1970.
|
|
VI. Physical Effects
MT-45 is a synthetic opioid with potent analgesic effects. It acts as a downer, causing sedation and respiratory depression. Short-term use is effective for pain management, but long-term use can lead to addiction, tolerance, and severe health issues. Overdose risks include fatal respiratory depression. Safe use requires strict dosing and medical supervision. Recent research explores its potency and risks compared to other opioids.  |
|
VII. Psychological Effects
MT-45, a piperazine derivative, affects serotonin and dopamine systems, leading to altered mood and perception. Immediate effects include euphoria and cognitive stimulation, while long-term use can result in dependence and psychological issues such as anxiety. Research indicates potential for significant mental health disturbances with chronic use.
 |
|
VIII. Culture
MT-45 is a synthetic opioid, classifying it as a downer. Short-term use provides pain relief and sedation, while long-term use can lead to dependence and tolerance. Overdose risks are high, potentially causing severe respiratory depression and fatal outcomes. Safe dosages are not well-established, with lower doses advised. Recent research emphasizes its high potency and associated health risks. Physical effects include drowsiness, constricted pupils, and respiratory depression.
 |